1 / 16

Clinical Outcomes of Coronary Stenting in Japanese Patients with and without Proton Pump Inhibitor

This study explores the impact of proton pump inhibitor (PPI) use on platelet aggregation and clinical outcomes in Japanese patients who underwent coronary stenting. Initial recommendations and subsequent research on PPI use in conjunction with antiplatelet therapy are discussed. Data from over 1000 patients reveal no significant differences in primary endpoints based on PPI usage. Comparison of platelet aggregation and clinical outcomes is presented, suggesting no adverse effects of PPI use in this context.

robertov
Download Presentation

Clinical Outcomes of Coronary Stenting in Japanese Patients with and without Proton Pump Inhibitor

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Clinical Outcomes Following Coronary Stenting in Japanese Patients with and without Proton Pump Inhibitor Hideki Shimomura, MD*1; Seiji Hokimoto, MD*2; Shuichi Oshima, MD*3; Koichi Nakao, MD*4; Yuji Miyao, MD*5; Hisao Ogawa, MD*2; for the Kumamoto Intervention Conference Study (KICS) investigators *1Division of Cardiology, Fukuoka Tokushukai Hospital, JAPAN *2Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, JAPAN *3Division of Cardiology, Kumamoto Central Hospital, JAPAN, *4Cardiovascular Center, Kumamoto Saiseikai Hospital, JAPAN *5National Hospital Organization Kumamoto Medical Center, JAPAN

  2. Background 1 1)AHA, ACC, ACG recommended in 2008 conference that PPI should be used in patients with dual antiplatelet therapy for prophylaxis of gastrointestinal bleeding. Need for Antiplatelet Therapy Assess GI Risk Factors History of Ulcer complication History of Ulcer Disease(non-bleeding) GI Bleeding Dual Antiplatelet Therapy Concomitant Anticoagulant Therapy Yes Test for H.pylori and treat if infected Yes No PPI More Than One Risk Factor: Age 60 years or More Corticosteroid Use Dyspepsia or GERD Symptoms Bhatt DL, et al. J Am Coll Cardiol 2008;52:1502-17 Bhatt DL, et al. Circulation 2008;118:1894-909 Bhatt DL, et al. Am J Gastroenterol 2008;103:2890-90 PPI

  3. Background 2 2)Several studies have indicated that concomitant use of clopidogrel and PPI is associated with reduced antiplatelet efficacy of clopidogrel, and increased adverse clinical outcomes after stent placement in patients with acute coronary syndrome(ACS). A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. Juurlink DN, et al. CMAJ 2009;180:713-8 Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome Ho PM, et al. JAMA 2009:301;937-44

  4. Background 3 3)However, recent studies show that concomitant use of clopidogrel and PPI was not related with the increased risk of clinical outcomes after coronary stenting. 4)Moreover, drug interaction between PPI and clopidogrel may be related with CYP2C19 gene polymorphism. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. O’Donoghue ML, et al. Lancet 2009; 6736:61525-7 Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Sibbing D, et al. Thromb Haemost 2009;101:714-9

  5. Purpose To examine the association between PPI use, measures of platelet aggregation, and clinical outcomes in Japanese patients treated with coronary stenting

  6. Methods 1 Subjects 1074 individuals undergoing PCI from April 2007 to March 2009 Male 810 (75%) Age 69 years (33 - 93) 2 groups aspirin 100mg+thienopyridine agent (clopidogrel 75mg or ticlopidine 200mg daily) + 1) PPI 2) no-PPI Use of PPI was left to the discretion of the attending physician

  7. Methods 2 Follow up period 12 months Primary endpoint Cardiovascular death Myocardial infarction Stroke Measurement in some patients (n=150) Platelet aggregation induced by 20μM adenosine diphosphate (ADP)

  8. Measurement of platelet aggregation Light transmission aggregometer Optical density method Platelet aggregation MCM Hema Tracer 313 AU*min (PAM12C, LMS Inc, Japan) Area=value time 10 min

  9. Table 1 Baseline characteristics of patients PPI (+) (-) p Number 454(42) 620(58) Male 337(74) 473(76) n.s Age (years) 70.1 68.9 n.s BMI(kg/m2) 23.6 24.1 n.s Current smoker 122(27) 462(75) n.s Hypertension 334(74) 484(78) n.s Dyslipidemia 254(56) 372(60) n.s Diabetets 165(36) 262(42) n.s Previous MI 82(18) 165(27) n.s Previous CABG 18(4) 55(9) n.s PAD 39(9) 54(9) n.s Renal dysfunction 64(14) 107(17) n.s

  10. Table 1 Baseline characteristics of patients continued PPI (+) (-) p Thienopyridine derivative Ticlopidine 218(48) 268(43) n.s Clopidogrel 236(52) 352(57) n.s Statin 302(67) 449(72) n.s Beta-blocker 146(32) 324(52) n.s ACEI/ARB 356(78) 145(23) n.s BMI, body mass index; MI, myocardial infarction; CABG, coronary artery bypass graft; PAD, peripheral arterial disease; ACEI, angiotensine converting enzyme inhibitor; ARB, angiotensin receptor blocker

  11. Fig. 1 Comparison of platelet aggregation between patients with or without PPI n.s AU*min 7000 6000 5000 Platelet aggregation 4000 3000 2000 1000 No-PPI PPI

  12. Table 2 Clinical outcomes PPI (+) (-) p Number 454(42) 620(58) Primary endpoint 18(4.0) 22(3.5) n.s CV death 3(0.7) 9(1.5) n.s MI 5(1.1) 9(1.5) n.s Stroke 10(2.2) 4(0.6) n.s Non-CV death 6(1.3) 14(2.3) n.s All-cause death 8(1.8) 24(3.9) n.s Stent thromobosis 2(0.4) 4(0.6) n.s rePCI 93(20.5) 101(16.3) n.s CABG 7(1.5) 7(1.1) n.s GI bleeding 0 7(1.1) n.s CV, cardiovascular; MI, myocardial infarction PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; GI, gastrointestinal

  13. Table 3 Primary endpoint and GI bleeding according to thienopyridine Ticlopidine Clopidogrel p Number 486(45%) 588(55%) Primary endpoint 22(4.5) 16(2.7) n.s CV death 7(1.4) 5(0.9) n.s MI 7(1.4) 6(1.0) n.s Stroke 8(1.6) 6(1.0) n.s GI bleeding 1(0.2) 6(1.0) n.s CV, cardiovascular; MI, myocardial infarction; GI, gastrointestinal

  14. Summary The ratio of clopidogrel use following PCI was very different from that of Western countries due to delay of adoption or permission of medical insurance system. Inhibition of platelet aggregation ex vivo was lower for patients on a PPI than for those not on a PPI, although statistically not significantly. There was no association between PPI use and risk of cardiovascular clinical outcomes. Gastrointestinal bleeding was not seen in PPI group.

  15. Conclusions Concomitant use of PPI and thienopyridine derivative (clopidogrel or ticlopidine) has no impact on cardiovascular events.

  16. Presenter Disclosure Information < Hideki Shimomura > Title Clinical Outcomes Following Coronary Stenting in Japanese Patients with and without Proton Pump Inhibitor DISCLOSURE INFORMATION There are no financial or other relations that could lead to a conflict of interest.

More Related